companies / oncomatryx-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-08 json
| total_raised | 2,700,0002.7M | ○ |
|---|---|---|
| founded | null | |
| hq | Derio, Spain | |
| industry | unknown | |
| stage | series-b+ |
Oncomatryx develops ADCs that target the tumour microenvironment and stroma rather than the tumour cells themselves to bypass resistance mechanisms. It targets metastatic solid tumours via clinical trials with stroma-directed payloads. The Bizkaia-based company frames the tumor stroma as the battlefield for next-generation oncology.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-03-01 | strategic | 2,700,0002.7M | null | ○ |
WordPress 7.0, Apache HTTP Server, GeneratePress 3.6.1, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, Elementor 3.35.5, WPML, Python, PHP, MySQL, jquery 3., apache
| fact | status | src |
|---|---|---|
| Strategic, $2.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |